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Premature Ventricular Complexes. Background: Frequent premature ventricular complexes (PVCs)
can be eliminated with an ablation procedure. Ablation success rates have been reported to be in the 80%
range. Reasons for failure of ablation have not been described in detail. The purpose of this study was to
determine whether the paucity of PVCs at the beginning of the ablation procedure affects the outcome.
Methods: Catheter ablation was attempted in a consecutive series of 194 patients (age: 50 ± 14 years,
91 male, ejection fraction: 56.4 ± 8.4%) with frequent idiopathic PVCs. Based on receiver operator
characteristics (ROC) analysis, patients were divided into 2 groups: Patients with frequent PVCs (32
PVCs within the first 30 minutes of the procedure: n = 135 [70%]); and patients with infrequent PVCs
(<32 PVCs within the first 30 minutes of the procedure: n = 59 [30%]). Procedural outcomes were
compared at 3 months postablation. A successful ablation was defined as a 80% reduction in the PVC
burden compared to baseline.
Results: A successful procedure was performed in 148 patients (76%) resulting in a decrease in the PVC
burden from 19.1 ± 13.6% to 0.38 ± 0.98%(P < 0.0001). Patients with frequent intraprocedural PVCs
had a higher success rate than patients with infrequent intraprocedural PVCs (85% vs. 56%, P = 0.0001).
Administration of sedation was no different in the 2 groups. The paucity of PVCs was independent of the
site of origin in predicting procedural failure (OR: 6.9, 95% CI: 3.0–16.2 P = 0.0001).
Conclusion: Paucity of PVCs at the beginning of an ablation procedure is associated with a lower ablation
success rate independent of the site of origin. (J Cardiovasc Electrophysiol, Vol. 25, pp. 1088-1092, October
2014)
infrequent PVCs, outcome, premature ventricular complexes
The reasons for failure of ablation of frequent premature ven-
tricular complexes (PVCs) have not been detailed. Inability to
reach the site of origin (SOO) may be a cause for failure, par-
ticularly in epicardial or intramural arrhythmias.1,2 Another
cause for failure is the inability to identify the SOO because
of imprecise mapping. In the absence of frequent PVCs, pace-
mapping is often used to identify the SOO. Pace-mapping is
less precise than activation mapping.3 The purpose of this
study was to assess whether the PVC prevalence at the onset
of the procedure impacts procedural outcome.
Methods
Patient Characteristics
The subjects of this study consisted of a consecutive se-
ries of 194 patients, (103 women [53%], mean age: 49.9 ±
14.3 years, mean ejection fraction [EF]: 56.4 ± 8.4%) that
were referred for catheter ablation (Table 1). Symptoms were
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absent in 35 patients, and 45 patients had PVC induced car-
diomyopathy (EF < 50%). The presence of coronary artery
disease, hypertensive heart disease, valvular heart disease, or
hypertrophic cardiomyopathy was ruled out by echocardio-
graphy, stress testing, coronary angiography, and/or cardiac
magnetic resonance imaging. Patients had failed 0.8 ± 0.4
antiarrhythmic medications including β-blocker and calcium
channel blocker therapy. All antiarrhythmic medications in-
cluding β-blockers and calcium channel blockers were dis-
continued at least 5 half-lives prior to the ablation procedure.
The mean number of PVC morphologies was 1.9 ± 2.2.
There was no difference in the number of PVC morpholo-
gies between infrequent and frequent PVC groups (P = 0.9).
Upon presentation in the electrophysiology laboratory, the
frequency of the predominant PVC was determined during
the initial 30 minutes after the patient was connected to the
ECG recording system. Patients were divided into 2 groups
depending on the prevalence of PVCs. If the number of PVC
within the first 30 minutes was <32 PVCs, the intraprocedu-
ral PVC burden was defined as infrequent (see below for the
basis of this cut-off value).
Holter Recordings
All patients had a 12-lead 24-hour Holter monitor prior
to the ablation procedure. The Holter was repeated 3 months
postablation and success was defined as a reduction of the
initial PVC burden by 80%.4-10 Before ablation, variabil-
ity of the PVC burden was assessed with 2 different Holter
monitors 171 ± 229 days apart. No significant variability
was found in the pre-ablation PVC burden (P = 0.42).
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TABLE 1
Clinical Characteristics
Patients (#) 194
Age 49.9 ± 14.3
Gender (M/F) 91/103
PVC burden (%) 18.4 ± 13.3
Symptomatic 159/194 (82%)
Ejection fraction (%) 56.4 ± 8.4
Medications pre-ablation
β-Blocker 121 (62%)
Calcium channel blocker 24 (12%)
Antiarrhythmics* 29 (15%)
Amiodarone 7 (4%)
Patients with previously failed procedures (n) 42 (22%)
*Anti-arrhythmics: propafenone, sotalol, mexiletine, flecainide.
Electrophysiology Study
After informed consent was obtained, conscious sedation
and analgesia was administered with propofol, midazolam,
fentanyl, and/or ketamine based on the attending physician’s
discretion and the patient’;s wishes. For repeat procedures
where a low intraprocedural PVC burden was felt to be the
limiting factor, sedation was minimized and limited to propo-
fol infusion with avoidance of midazolam or other longer act-
ing sedatives. Multiple quadripolar electrode catheters were
advanced via a femoral vein to the right ventricular apex, the
His bundle position, and the high right atrium. After vascular
access was obtained, 3,000 units of heparin were adminis-
tered. If arterial access was necessary, additional heparin was
administered to achieve an activated clotting time of 250–300
seconds. Surface electrograms were recorded in combination
with bipolar intracardiac electrograms (EP Med Systems,
West Berlin, NJ, USA).
In the absence of frequent PVCs, sedation was discontin-
ued and isoproterenol was administered with a dose up to
20 mcg/minute. Several maneuvers were performed to trig-
ger PVCs: (1) atrial burst pacing, (2) ventricular burst pacing
with cycle lengths of 500–200 milliseconds, (3) programmed
ventricular stimulation with 4 extrastimuli11 at 3 drive cycle
lengths of 350, 400, and 600 milliseconds. Atrial and ven-
tricular pacing was performed during isoproterenol infusion
and during isoproterenol withdrawal. Outcome at 3 months
was analyzed depending on the PVC prevalence within the
first 30 minutes of the procedure, independent of the success
of provocative measures in triggering PVCs.
Mapping and Ablation
A 3-dimensional electroanatomical mapping system
(CARTO, Biosense Webster, Diamond Bar, CA, USA) was
used in all patients. Mapping was performed with a 3.5-mm-
open-irrigation-tip catheter (Thermocool Navistar, Biosense
Webster). Activation mapping was performed to identify the
SOO of frequent PVCs. In the setting of infrequent ventric-
ular ectopy, pace mapping was used to identify the SOO.
At the SOO of a particular arrhythmia, pace mapping was
performed and a matching pace map was identified when
10/12 leads matched between the paced QRS complex and
the targeted PVC.
An intramural focus was considered if mapping on either
wall of the ventricular cavity showed early activation yet
pace-mapping did not match with the targeted morphology
of the PVC. An epicardial SOO was defined as a site within
the coronary venous system or the epicardial space where
the earliest activation time with a matching pace-map was
identified.
Radiofrequency energy was delivered for 60–120 seconds
at the SOO. An impedance drop of 10 ohms was targeted
with a power of 30–50 watts. If radiofrequency energy was
delivered in the aortic cusps or within the coronary venous
system, an initial power of 15–20 watts was used.
Follow-Up
Patients were seen in follow-up at 3–6 and 12–48 months
postablation. Subsequently, patients were seen on an as-
needed basis. Antiarhythmic medications were discontinued
after an effective ablation procedure.
Statistical Analysis
Continuous variables are expressed as mean ± 1 standard
deviation and were compared with Student’s t-test. Categor-
ical variables were compared with the chi-square test. If the
sample size was smaller than 5 in a given cell, Fisher’s exact
test was used. Logistic regression was used for multivariate
analysis of independent variables. A P value of <0.05 was
considered statistically significant. The PVC prevalence was
quantified for the first 30 minutes of the procedure. A receiver
operator characteristics (ROC) curve was created to assess
whether there was a PVC burden that separated patients with
successful ablation procedures from patients with a failed
ablation procedure.
Results
PVC Burden and Outcome
A successful procedure was performed in 148 patients
(76%) resulting in a decrease in the PVC burden from 19.1
± 13.6% to 0.38 ± 0.98% (P < 0.0001) in these patients
(Table 2). Initially, about one-third of patients (30%) under-
going a PVC ablation procedure had infrequent intraproce-
dural PVCs and had a lower success rate than patients with
frequent PVCs at the onset of the procedure (56% vs. 85% re-
spectively, P = 0.0001). A cut-off value of 32 PVCs/30 min-
utes best-separated patients with successful outcome from
patients with a failed ablation (sensitivity: 78%, specificity:
56%, P < 0.0001, AUC = 0.68, Fig. 1).
In patients with infrequent intraprocedural PVCs, the PVC
count during the initial 30 minutes was 7.9 ± 10 compared
to 493 ± 409 in patients with frequent PVCs (P < 0.0001)
The mean PVC count during the first 30 minutes of the
procedure was significantly higher in patients with a suc-
cessful procedure than in patients who had a failed ablation
procedure (395 ± 420 vs. 194 ± 327, P = 0.0001).
In patients with infrequent intraprocedural PVCs, the PVC
burden was reduced from 11.4 ± 10.4% to 3.9 ± 7.6% (P =
0.0001) at 3 months postablation. In patients with frequent
intraprocedural PVCs, the PVC burden was reduced from
21.7 ± 13.2% to 2.9 ± 7.0% (P = 0.0001).
When the PVC burden during the first 30 minutes of
the mapping procedure was compared to the preprocedure
24-hour Holter monitor, the burden was substantially lower in
patients with infrequent intraprocedural PVCs (0.38 ± 0.49%
intraprocedurally compared to 11.4 ± 10.4% during the
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TABLE 2
Comparison of Patients with Frequent vs Infrequent PVCs
Variable Frequent PVCs Infrequent PVCs P Value
Patients (#) 135 (70%) 59 (30%)
Gender (M/F) 65/70 26/33 0.6
Age (years) 49.9 ± 14.6 49.7 ± 13.7 0.83
Symptoms (%) 108 (80%) 51 (86%) 0.28
Ejection fraction (%) 55.6 ± 9.5 58.3 ± 4.5 0.26
PVC-cardiomyopathy 38 (28%) 7 (12%) 0.01
30 minute
intraprocedural
PVC burden (%)
21.5 ± 16.5 0.38 ± 0.49 0.0001
Holter PVC burden
pre-RF (%)
21.7 ± 13.2 11.4 ± 10.4 0.0001
Sedation/analgesia
Midazolam 100 (74%) 37 (63%) 0.84
Propofol 55 (41%) 22 (37%) 0.69
Fentanyl 84 (62%) 27 (46%) 0.17
Effective ablation at 3
months
115 (85%) 33 (56%) 0.0001
SOO 0.67
Epicardial 17 (13%) 8 (14%)
Cusp 17 (13%) 10 (17%)
Papillary muscle 15 (11%) 7 (12%)
RVOT 45 (33%) 27 (46%)
Fascicular 1 (0.7%) 0
Intramural 9 (6.7%) 1 (1.7%)
LVOT 12 (8.8%) 3 (5.1%)
Parahisian 6 (4.4%) 1 (1.7%)
Mitral annulus 6 (4.4%) 1 (1.7%)
Tricuspid annulus 3 (2.2%) 0
LV posterobasal 2 (1.4%) 1 (1.7%)
LV posteroseptal 1 (0.7%) 0
Aortomitral
continuity
1 (0.7%) 0
Procedure time
(minutes)
283.4 ± 100.3 289 ± 98.5 0.48
RF time (minutes) 17.2 ± 12.6 17.1 ± 15 0.53
Fluoroscopy time
(minutes)
46.1 ± 24 45.1 ± 23 0.91
LV = left ventricular; LVOT = left ventricular outflow tract; PVC = pre-
mature ventricular complex; RF = radiofrequency ablation; RVOT = right
ventricular outflow tract; SOO = site of origin.
24-hour Holter; P = 0.0001). In patients with frequent
intraprocedural PVCs, the PVC burden during the initial
30 minutes was no different compared to the preprocedu-
ral Holters (21.5 ± 16.5% intraprocedurally compared to
21.7 ± 13.2% during the 24-hour Holter; P = 0.70).
In patients presenting with infrequent PVCs, there was no
significant difference between the PVC burden pre-ablation
when 2 preprocedural Holters were compared (10.7 ± 11.5%
vs. 12.7 ± 11.3%, P = 0.89). This was also the case for
patients with frequent PVCs prior to the procedure (21.5 ±
13.6% vs. 21.4 ± 13.6%, P = 0.35).
Impact of Sedation and Analgesia
Midazolam was used in 137 patients, propofol in 77 pa-
tients, fentanyl in 111 patients, and ketamine in 8 patients dur-
ing the mapping procedure. There was no difference between
infrequent and frequent intraprocedural PVC groups with re-
spect to which, if any, sedatives, narcotics, or analgesics were
given (P values for midazolam, propofol, fentanyl, and ke-
tamine were 0.84, 0.69, 0.17, and 0.34, respectively).
Impact of Site of Origin
The paucity of PVCs was associated with procedural fail-
ure independent of the SOO (OR: 6.9, 95% CI: 3.0–16.2;
P = 0.0001). The sites of origin between intraprocedural in-
frequent and frequent PVC groups were similar (P = 0.67).
In 35 patients, PVCs originated from the epicardium or intra-
mural sites. The success rates for these sites of origins was
lower compared to other sites (57% vs. 81%; P = 0.003).
Furthermore, outcomes in this subset of patients were sim-
ilar regardless of whether they had frequent or infrequent
intraprocedural PVCs (P = 0.37).
Impact of Isoproterenol Administration
In patients with infrequent PVCs, isoproterenol was ad-
ministered. In patients in whom the PVC prevalence in-
creased with isoproterenol (24/59), continued isoproterenol
infusion was used to map the origins of PVCs. In these 24
patients, the success rate at 3 months was higher compared
to patients in whom isoproterenol failed to increase the in-
traprocedural PVC prevalence (79% vs. 42%, P = 0.008) and
their outcome was similar compared to patients with frequent
PVCs at the onset of the procedure (79% vs. 85%, P = 0.42).
Yield of Pacing Maneuvers
In 4/59 patients, pacing maneuvers resulted in a repro-
ducibly inducible PVCs; however, these patients did not have
a better outcome at 3 months compared to the other patients
with frequent intraprocedural PVCs.
Repeat Procedures
Among the 19 patients with repeat procedures, 12 had in-
frequent PVCs during the index procedure and 3 (15%) had
infrequent PVCs during the repeat procedure. All 3 of these
patients also had infrequent PVCs during the index proce-
dure. A total 12 of 19 patients had effective ablation proce-
dures and ablation failed in only one patient due to infrequent
PVCs during the second procedure. In the remaining 6 pa-
tients with a failed procedure, the SOO could not be reached
with the ablation catheter.
Follow-Up
Patients were followed for a mean of 19 ± 18 months after
the ablation procedure. Nineteen patients required a repeat
procedure. A second procedure was required more often in
patients with infrequent intraprocedural PVCs compared to
patients with frequent intraprocedural PVCs (n = 12 [20%]
vs. n = 7 [5.2%], P = 0.001).
Discussion
Main Findings
This study demonstrates that the PVC burden within the
first 30 minutes of the electrophysiology procedure impacted
on the procedural outcome at 3 months. Patients with infre-
quent intraprocedural PVCs had a significantly lower success
rate, independent of the SOO of PVCs, as compared to pa-
tients with frequent intraprocedural PVCs.
PVC Burden During the Mapping Procedure
In a subset of patients with frequent PVCs during baseline
Holter, the PVC burden was substantially reduced at the onset
of the mapping procedure. Day-to-day variability of the PVC
burden might account for this observation; however, multiple
preprocedural Holters failed to show a significant variabil-
ity that might have accounted for the lack of PVCs in some
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Figure 1. ROC analysis for the PVC
count within the first 30 minutes of the pro-
cedure. A PVC count <32 within the first
30 minutes of the procedure had a sen-
sitivity of 78% and a specificity of 56%
(area under curve: 0.68, P = 0.0001;
95% CI: 0.59–0.78) differentiating pa-
tients with a successful procedure from
patients with a failed procedure.
patients at the onset of the procedure. Other factors might
impact on the intraprocedural PVC prevalence. Hormones,
particularly in women, may impact on PVC prevalence and
may account for infrequent PVCs during parts of the men-
strual cycle.12 However, there was no gender difference be-
tween patients with and without infrequent intraprocedural
PVCs. Sedation can decrease spontaneous and inducible ven-
tricular arrhythmias.13,14 However, sedation regimens were
no different in patients with infrequent intraprocedural PVCs
compared to patients with frequent intraprocedural PVCs. A
higher susceptibility to sedation in some patients with fre-
quent PVCs appears plausible and could have impacted on
the procedural outcome. The baseline PVC burden in patients
with infrequent intraprocedural PVCs was lower compared to
patients in whom this was not the case and the lower burden
might identify a population with a higher susceptibility to
sedation. Longer acting sedatives like midazolam should be
used with caution for sedation although in this study, patients
exposed to midazolam were not more likely to have infre-
quent intraprocedural PVCs compared to patients in whom
midazolam was not used. Nevertheless, when sedation was
minimized during a second procedure in patients with un-
successful ablations due to infrequent intraprocedural PVCs,
PVCs were frequent enough to allow for identification of the
SOO with activation mapping in most patients. The protocol
of “minimal” sedation invoked among patients with repeat
ablations included avoidance of longer acting sedatives like
midazolam and use of short acting sedatives including propo-
fol that could be titrated to the patients needs and could be
discontinued in the absence of PVCs. This strategy resulted
in a successful second ablation procedure in most patients.
With this strategy, the prevalence of patients with infrequent
PVCs was cut in half during repeat procedures (from 30% to
15%) despite that fact that most patients with repeat proce-
dures had infrequent intraprocedural PVCs during the index
ablation.
The lack of PVCs at the procedural onset could be over-
come by administration of isoproterenol in some patients
with infrequent PVCs and in these patients the outcome was
similar compared to patients with frequent intraprocedural
PVCs. Other maneuvers including pacing failed to improve
outcome. This is important as the response to isoproterenol
can be assessed prior to the electrophysiology procedure and
predict likelihood of a successful ablation.
Mapping Technique
In the absence of frequent PVCs, pace-mapping is the
predominant mapping technique. The spatial resolution and
thereby the accuracy of pace-mapping has been demonstrated
to be lower as compared to activation mapping.3 This study
suggests that reliance primarily on pace-mapping results in
a lower success rate most likely due to less precise mapping.
Activation mapping is key in identifying the SOO in certain
anatomic locations such as the aortic cusps where pacing
with high output may be required in order to capture the
ventricular myocardium. This may cause unintended capture
of more distant myocardium resulting in an altered QRS
morphology despite accurate catheter positioning at the SOO.
For intramural sites of origin, activation mapping is equally
important in order to identify endocardial breakthrough sites
that are critical for selection of appropriate ablation sites.2
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Appropriate Ablation Endpoint
The presence of frequent PVCs prior to radiofrequency
ablation and the absence of PVCs postablation for a certain
period of time is a reasonable endpoint of the ablation pro-
cedure. In the absence of frequent PVCs, ablation endpoints
become less clear and this uncertainty may prompt the oper-
ator to deliver more ablation lesions.
Limitations
This is a retrospective analysis of a small series of pa-
tients and data will need to be collected prospectively to de-
termine the exact impact of sedation on the intraprocedural
PVC prevalence. However, patients with infrequent intrapro-
cedural PVCs were given the same sedatives compared to
patients with frequent intraprocedural PVCs arguing against
the impact of sedation as the only factor for infrequent in-
traprocedural PVCs.
Clinical Implications
Frequency of intraprocedural PVCs impact on long-term
success for ablation of idiopathic PVCs. If an ablation is per-
formed in a patient with frequent PVCs who presents on the
day of the procedure with infrequent PVCs, efforts should
be maximized to increase the intraprocedural PVC burden.
If this can be achieved with administration of isoproterenol,
the success rate is similar to patients with frequent intrapro-
cedural PVCs. Preprocedural monitoring and infusion of iso-
proterenol prior to the invasive procedure therefore may help
to identify a group of patients in whom a mapping and abla-
tion procedure will be beneficial. For repeat procedures, long
acting sedatives should be avoided.
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